Manuel Suarez Barcelo, MD
Internal Medicine · North Miami, FLNPI 1669461042
Payments from drug & device makers
Across 461 payments — averaging $380.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$46K
- Lilly USA, LLC$37K
- Sunovion Pharmaceuticals Inc.$23K
- Sumitomo Pharma America, Inc.$22K
- Mylan Specialty L.p.$22K
- Mylan Inc.$12K
- plus $13K from 18 others
What the payments were for
- Consulting fees$13,4408%
- Speaking & faculty fees$120,58469%
- Travel & lodging$33,04219%
- Food & beverage$8,3055%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 98 | $46,033 |
| Lilly USA, LLC | 134 | $37,247 |
| Sunovion Pharmaceuticals Inc. | 58 | $23,011 |
| Sumitomo Pharma America, Inc. | 40 | $22,460 |
| Mylan Specialty L.p. | 42 | $21,627 |
| Mylan Inc. | 15 | $12,056 |
| Xeris Pharmaceuticals, Inc. | 14 | $6,762 |
| Viatris Specialty LLC | 7 | $4,844 |
| Bayer | 10 | $274 |
| Amgen | 9 | $215 |
| Otsuka America Pharmaceutical, Inc. | 4 | $154 |
| GSK | 5 | $114 |
| Exact Sciences | 4 | $96 |
| Avanir Pharmaceuticals, Inc. | 4 | $93 |
| Teva Pharmaceuticals USA, Inc. | 4 | $89 |
| Novartis | 4 | $75 |
| AstraZeneca | 1 | $50 |
| Eisai Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Pfizer | 1 | $24 |
| Johnson & Johnson | 1 | $24 |
| Cvrx, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$64,986
- Yupelri$34,491
- TRULICITY$26,815
- LONHALA MAGNAIR$22,185
- GVOKE HYPOPEN$6,517
- Wixela Inhub$2,789
- ZEPBOUND$121
How this compares
$175,371 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 138 | $116,127 |
| EliquisApixaban | 245 | $84,198 |
| GemtesaVibegron | 331 | $82,725 |
| XareltoRivaroxaban | 197 | $61,408 |
| TivicayDolutegravir Sodium | 48 | $53,931 |
| Risperdal ConstaRisperidone Microspheres | 38 | $36,175 |
| FarxigaDapagliflozin Propanediol | 111 | $35,849 |
| AptiomEslicarbazepine Acetate | 40 | $24,519 |
| ProcritEpoetin Alfa | 21 | $23,940 |
| Chlorpromazine Hcl | 36 | $14,735 |
| Risperidone ErRisperidone Microspheres | 14 | $13,037 |
| OzempicSemaglutide | 12 | $11,966 |
| Potassium Chloride | 124 | $11,764 |
| MyrbetriqMirabegron | 21 | $11,206 |
| Levetiracetam | 199 | $9,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Risperdal Consta, Procrit | $24 | $121,523256 claims |
| Lilly USA, LLCTrulicity | $37,247 | $116,127138 claims |
| PfizerEliquis | $24 | $84,198245 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22,460 | $82,725331 claims |
| AstraZenecaFarxiga | $50 | $35,849111 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $23,011 | $24,51940 claims |
| Mylan Inc.Atorvastatin Calcium | $12,056 | $8,164501 claims |
| NovartisEntresto | $75 | $5,51016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in North Miami
- David JativaNorth Miami$6.2M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.